KaloBios Regains the Global Rights to KB001-A, Ending Their Collaboration with Sanofi Pasteur

KaloBios Ends Drug Development Deal with Sanofi Pasteur

In Partnering & Investment by Cecile

KaloBios Regains the Global Rights to KB001-A, Ending Their Collaboration with Sanofi Pasteur

The San Francisco based pharmaceutical company KaloBios saw its extended trades fall by 12 percent yesterday after it was announced that the pharmaceutical giant Sanofi Pasteur has agreed to ending their licensing and collaborative agreement, handing over the full rights of the KB001-A drug development plan to KaloBios.

The Californian company is still seeking a partner to financially support their studies of the drug, for which it has completed the full enrollment of 180 patients for a phase 2 cystic fibrosis study.

When the companies entered a collaboration in 2010, they were both developing the drug for different purposes. Sanofi Pasteur was developing KB001-A, a patented monoclonal antibody that targets Pseudomonas aeruginosa bacteria (Pa), for PA caused pneumonia prevention in intensive care situations. KaloBios, on the other hand, was developing the drug for chronic Pa caused lung infections in cystic fibrosis patients.

David Pritchard, the President and CEO of KaloBios, sees the end of this collaboration as a positive event, which ‘not only provides us (KaloBios) with full unencumbered rights to our cystic fibrosis indication, but will enable us to seek a partner with established capabilities in additional indications as well as in territories outside of the United States.’

We will immediately embark on a process to identify a partner with a focus on infectious disease, hospital pharmaceuticals, or cystic fibrosis who can accelerate and financially support the pivotal studies for KB001-ADavid Pritchard, President and CEO of KaloBios

Sanofi Pasteur will, however, be entitled to receive up to 10 percent of certain sub-license payments received in the event KaloBios successfully re-partners KB001-A. This is subject to a separate $40 million cap on the aggregate amount of sub-license payments to be shared with Sanofi Pasteur.

KaloBios has received Orphan Drug designation for Kb001-A from the FDA and the European Medicines Agency for the treatment of Pa caused lung infection in cystic fibrosis patients.

KaloBios had previously completed a Phase 1/2 study with KB001 in 35 patients colonized with Pa, which demonstrated approximately a 50 percent reduction in Ventilator Associated Pneumonia.

Read more about it here: KaloBios Regains Global Rights To KB001-A, Ends Deal With Sanofi Pasteur